Literature DB >> 8914662

6th Meeting of the European Neurological Society. The Hague, The Netherlands, 8-12 June 1996. Abstracts.

.   

Abstract

Mesh：

Year:  1996        PMID： 8914662

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  4 in total

1.  A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis.

Authors:  M B Bornstein; A Miller; S Slagle; M Weitzman; E Drexler; M Keilson; V Spada; W Weiss; S Appel; L Rolak
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

2.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; R P Lisak; L W Myers; H S Panitch; J W Rose; R B Schiffer
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

3.  Multiple sclerosis: trial of a synthetic polypeptide.

Authors:  M B Bornstein; A I Miller; D Teitelbaum; R Arnon; M Sela
Journal:  Ann Neurol       Date:  1982-03       Impact factor: 10.422

4.  A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.

Authors:  M B Bornstein; A Miller; S Slagle; M Weitzman; H Crystal; E Drexler; M Keilson; A Merriam; S Wassertheil-Smoller; V Spada
Journal:  N Engl J Med       Date:  1987-08-13       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.